Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KRMD logo KRMD
Upturn stock ratingUpturn stock rating
KRMD logo

Repro Med Systems Inc (KRMD)

Upturn stock ratingUpturn stock rating
$3.58
Last Close (24-hour delay)
Profit since last BUY13.65%
upturn advisory
Consider higher Upturn Star rating
BUY since 35 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.5

1 Year Target Price $5.5

Analysts Price Target For last 52 week
$5.5Target price
Low$1.86
Current$3.58
high$5.05

Analysis of Past Performance

Type Stock
Historic Profit 6.88%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 165.18M USD
Price to earnings Ratio -
1Y Target Price 5.5
Price to earnings Ratio -
1Y Target Price 5.5
Volume (30-day avg) 5
Beta 0.43
52 Weeks Range 1.86 - 5.05
Updated Date 07/1/2025
52 Weeks Range 1.86 - 5.05
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.12

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.1%
Operating Margin (TTM) -12.92%

Management Effectiveness

Return on Assets (TTM) -13.09%
Return on Equity (TTM) -29.87%

Valuation

Trailing PE -
Forward PE 188.68
Enterprise Value 160179688
Price to Sales(TTM) 4.71
Enterprise Value 160179688
Price to Sales(TTM) 4.71
Enterprise Value to Revenue 4.57
Enterprise Value to EBITDA -17.15
Shares Outstanding 46141000
Shares Floating 33853187
Shares Outstanding 46141000
Shares Floating 33853187
Percent Insiders 7.6
Percent Institutions 51.82

Analyst Ratings

Rating 2
Target Price 5.5
Buy -
Strong Buy 4
Buy -
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Repro Med Systems Inc

stock logo

Company Overview

overview logo History and Background

Repro Med Systems, Inc., doing business as KORU Medical Systems, was founded to develop, manufacture, and market medical devices for various therapies. It has evolved to focus on home infusion solutions.

business area logo Core Business Areas

  • Infusion Therapy: KORU Medical Systems focuses on infusion therapy, particularly subcutaneous infusion. This includes devices and consumables used for delivering medications and fluids directly under the skin.

leadership logo Leadership and Structure

KORU Medical Systems has a leadership team comprising executives with experience in medical devices and finance. The organizational structure involves departments for R&D, manufacturing, sales, marketing, and administration.

Top Products and Market Share

overview logo Key Offerings

  • Freedom System: The Freedom System, including the Freedom60 and FreedomEdge Syringe Infusion Drivers and related consumables (HIgH-Flo Subcutaneous Safety Needle Sets and tubing), provides ambulatory infusion for patients. Market share data is not publicly available, but its competitors include Smiths Medical and Baxter International. High-Flo needles aim to maximize flow rates of infusates. Revenue is mainly related to the sale of the Freedom System.

Market Dynamics

industry overview logo Industry Overview

The infusion therapy market is driven by the increasing prevalence of chronic diseases and the growing demand for home healthcare. Advancements in infusion technology and the development of biocompatible materials also contribute to market growth.

Positioning

KORU Medical Systems is positioned in the ambulatory infusion segment, focusing on subcutaneous delivery. Its competitive advantage lies in its user-friendly devices and specialized needle sets. It competes with larger players in the infusion pump market.

Total Addressable Market (TAM)

The TAM for infusion therapy is estimated to be multi-billion dollars globally. KORU Medical Systems targets a niche within this market, focusing on specific infusion needs and patient populations. Actual numbers vary across industries and depend on the study. Positioned to grow within its focused market by increasing adoption within the subcutaneous market.

Upturn SWOT Analysis

Strengths

  • Specialized focus on subcutaneous infusion
  • User-friendly device design
  • Proprietary needle technology
  • Strong brand recognition within its niche

Weaknesses

  • Limited product portfolio
  • Dependence on a single core technology
  • Small market capitalization relative to competitors
  • Reliance on third-party manufacturers

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships with pharmaceutical companies
  • Geographic expansion into international markets
  • Development of next-generation infusion devices

Threats

  • Competition from larger medical device companies
  • Technological advancements by competitors
  • Changes in healthcare regulations and reimbursement policies
  • Product recalls or safety concerns

Competitors and Market Share

competitor logo Key Competitors

  • BDX
  • BAX
  • ITCI

Competitive Landscape

KORU Medical Systems faces competition from larger medical device companies with broader product portfolios and greater resources. Its competitive advantage lies in its focus on subcutaneous infusion and user-friendly devices.

Growth Trajectory and Initiatives

Historical Growth: Discuss KORU Medical Systems' growth trends over the past years, focusing on sales of its Freedom system and any new market penetration.

Future Projections: Provide projections for KORU Medical Systems' future growth based on analyst estimates and the company's strategic initiatives.

Recent Initiatives: Highlight recent strategic initiatives undertaken by KORU Medical Systems, such as new product launches, partnerships, or acquisitions.

Summary

KORU Medical Systems specializes in subcutaneous infusion therapy with its Freedom System. It is a smaller player facing stiff competition from larger medical device companies. Its strengths include a specialized focus and user-friendly design. Growth opportunities lie in expanding into new markets and therapeutic areas, while it needs to watch out for competitive advancements and healthcare regulations.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Repro Med Systems Inc

Exchange NASDAQ
Headquaters Mahwah, NJ, United States
IPO Launch date 1996-03-20
President, CEO & Director Ms. Linda M. Tharby
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 80
Full time employees 80

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.